AU
CA
NZ
UK
US
IND
Kalkine has a fully transformed New Avatar.
Last update at 2026-03-10T20:00:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
3 of Wall Street’s Favorite Stocks in Dangerous Territory
Mon 12 May 25, 04:43 AMDown -49.47% in 4 Weeks, Here's Why Myriad (MYGN) Looks Ripe for a Turnaround
Thu 08 May 25, 01:35 PMMyriad Genetics, Inc. (NASDAQ:MYGN) Just Reported Earnings, And Analysts Cut Their Target Price
Thu 08 May 25, 12:54 PMQ1 Earnings Recap: AbbVie (NYSE:ABBV) Tops Therapeutics Stocks
Thu 08 May 25, 03:33 AMWhy Myriad Genetics (MYGN) Stock Is Down Today
Wed 07 May 25, 06:09 PMMYGN Q1 Earnings Top Estimates, Stock Down on Weak 2025 Outlook
Wed 07 May 25, 12:34 PMMyriad (MYGN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Tue 06 May 25, 11:30 PMMyriad Genetics (NASDAQ:MYGN) Misses Q1 Sales Targets, Stock Drops 14.5%
Tue 06 May 25, 09:46 PM| Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
| Income before tax | -140.60000M | -57.10000M | -94.00000M | 0.20M | 0.20M |
| Minority interest | 0.00000M | 0.00000M | - | -0.10000M | -0.20000M |
| Net income | -112.00000M | -27.20000M | -53.00000M | 4.60M | 4.60M |
| Selling general administrative | 514.70M | 599.80M | - | 510.10M | 555.50M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 476.40M | 493.00M | 209.00M | 650.10M | 650.10M |
| Reconciled depreciation | 52.70M | 62.80M | - | 72.00M | 73.00M |
| Ebit | -123.70000M | -48.70000M | -87.00000M | 13.10M | 13.10M |
| Ebitda | -67.80000M | 14.10M | -52.00000M | 86.10M | 86.10M |
| Depreciation and amortization | 55.90M | 62.80M | 35.00M | 73.00M | 73.00M |
| Non operating income net other | - | - | - | 19.20M | 4.40M |
| Operating income | -123.70000M | -48.70000M | -87.00000M | 7.60M | 7.60M |
| Other operating expenses | 802.10M | 879.30M | 387.00M | 842.40M | 842.40M |
| Interest expense | 3.20M | 6.60M | 0.00000M | 12.00M | 12.00M |
| Tax provision | -28.60000M | -29.90000M | - | -23.70000M | -4.40000M |
| Interest income | 2.60M | 0.70M | - | 3.00M | 3.20M |
| Net interest income | -0.60000M | -5.90000M | - | -7.80000M | -8.80000M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | 99.70M | - |
| Other items | - | - | - | - | - |
| Income tax expense | -28.60000M | -29.90000M | -82.00000M | -4.40000M | -4.40000M |
| Total revenue | 678.40M | 690.60M | 299.00M | 851.10M | 851.10M |
| Total operating expenses | 600.10M | 681.70M | 296.00M | 641.40M | 641.40M |
| Cost of revenue | 202.00M | 197.60M | 90.00M | 201.00M | 201.00M |
| Total other income expense net | -16.90000M | -8.40000M | 7.00M | 0.10M | 0.10M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -112.00000M | -27.20000M | - | -199.60000M | 4.40M |
| Net income applicable to common shares | -112.00000M | -27.20000M | -106.20000M | -199.50000M | 4.60M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
| Total assets | 1198.70M | 1320.70M | 1418.00M | 1562.70M | 1562.70M |
| Intangible assets | 379.70M | 404.10M | 576.00M | 684.70M | 684.70M |
| Earning assets | - | - | - | - | - |
| Other current assets | 20.40M | 38.40M | - | 41.70M | 41.70M |
| Total liab | 312.90M | 352.90M | 537.00M | 473.80M | 473.80M |
| Total stockholder equity | 885.80M | 967.80M | - | 1088.90M | 1088.90M |
| Deferred long term liab | - | - | - | 26.60M | 82.60M |
| Other current liab | 93.70M | 156.50M | 40.40M | 3.40M | 3.40M |
| Common stock | 0.80M | 0.80M | 0.80M | 0.70M | 0.70M |
| Capital stock | 0.80M | 0.80M | - | 0.70M | 0.70M |
| Retained earnings | -366.20000M | -254.20000M | -227.00000M | 25.60M | 25.60M |
| Other liab | 44.80M | 69.30M | 116.50M | 58.10M | 122.50M |
| Good will | 286.80M | 239.20M | 329.00M | 417.20M | 417.20M |
| Other assets | 8.40M | 1.60M | 2.30M | - | - |
| Cash | 56.90M | 258.40M | 117.00M | 93.20M | 93.20M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 137.20M | 204.30M | 145.00M | 117.80M | 117.80M |
| Current deferred revenue | 0.60M | 5.20M | - | 2.20M | 2.20M |
| Net debt | 88.10M | -166.10000M | 120.00M | 140.30M | 140.30M |
| Short term debt | 14.10M | 13.00M | 13.00M | 78.90M | 78.90M |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | 145.00M | 92.30M | 237.00M | 233.50M | 233.50M |
| Other stockholder equity | 1260.10M | 1226.30M | -2.30000M | 1068.00M | 1068.00M |
| Property plant equipment | 187.30M | 125.30M | 100.40M | 103.00M | 57.30M |
| Total current assets | 274.60M | 484.80M | 389.00M | 348.60M | 348.60M |
| Long term investments | 54.80M | 59.00M | - | 37.00M | 54.90M |
| Net tangible assets | 212.20M | 317.80M | -24.70000M | -14.70000M | -13.00000M |
| Short term investments | 58.00M | 81.40M | 33.00M | 43.70M | 43.70M |
| Net receivables | 101.60M | 91.30M | 89.00M | 138.60M | 138.60M |
| Long term debt | - | - | - | 224.40M | 233.50M |
| Inventory | 20.10M | 15.30M | 27.00M | 31.40M | 31.40M |
| Accounts payable | 28.80M | 29.60M | 20.50M | 33.30M | 33.30M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -8.90000M | -5.10000M | -2.00000M | -5.40000M | -5.40000M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | 0.70M | 0.70M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | -173.90000M | 25.60M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 15.50M | 8.30M | 25.00M | 66.00M | 1214.10M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 924.10M | 835.90M | 1029.00M | 1214.10M | 1214.10M |
| Capital lease obligations | 145.00M | 92.30M | - | 70.40M | - |
| Long term debt total | - | - | - | 224.40M | 233.50M |
| Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
| Investments | -77.50000M | -86.70000M | 71.80M | 29.50M | 0.70M |
| Change to liabilities | -8.50000M | -17.40000M | -2.80000M | -9.10000M | 2.60M |
| Total cashflows from investing activities | -77.50000M | 274.40M | 56.00M | 19.30M | -286.40000M |
| Net borrowings | - | -226.40000M | -226.40000M | -9.60000M | 223.60M |
| Total cash from financing activities | -8.00000M | -150.60000M | -2.00000M | 182.30M | 182.30M |
| Change to operating activities | -80.50000M | 55.10M | -5.60000M | 4.40M | -2.40000M |
| Net income | -112.00000M | -27.20000M | -53.00000M | 4.60M | 4.60M |
| Change in cash | -192.40000M | 141.40M | -46.00000M | -17.70000M | -17.70000M |
| Begin period cash flow | 258.80M | 117.00M | 163.00M | 110.90M | 110.90M |
| End period cash flow | 66.40M | 258.40M | 117.00M | 93.20M | 93.20M |
| Total cash from operating activities | -106.30000M | 18.20M | -73.00000M | 83.70M | 83.70M |
| Issuance of capital stock | - | - | - | - | - |
| Depreciation | 52.70M | 62.80M | 35.00M | 73.00M | 73.00M |
| Other cashflows from investing activities | - | - | - | - | -278.50000M |
| Dividends paid | - | - | - | -340.00000M | 340.00M |
| Change to inventory | -2.90000M | 1.60M | 2.00M | 8.00M | 8.00M |
| Change to account receivables | -10.30000M | -8.80000M | -21.00000M | -18.20000M | -18.20000M |
| Sale purchase of stock | - | 0.00000M | - | -50.00000M | -50.00000M |
| Other cashflows from financing activities | -14.30000M | -16.00000M | 105.00M | 678.60M | 678.60M |
| Change to netincome | 54.50M | -137.80000M | 150.80M | 71.40M | 50.20M |
| Capital expenditures | 45.30M | 18.00M | 7.00M | 8.60M | 8.60M |
| Change receivables | - | - | - | 64.60M | -18.90000M |
| Cash flows other operating | - | - | - | 59.70M | -35.80000M |
| Exchange rate changes | - | - | - | 0.50M | 2.70M |
| Cash and cash equivalents changes | - | - | - | 70.50M | -17.70000M |
| Change in working capital | -101.50000M | 120.40M | 59.30M | -37.10000M | -37.10000M |
| Stock based compensation | 38.10M | 36.30M | - | 33.50M | 33.50M |
| Other non cash items | 48.30M | -139.40000M | 6.00M | -3.40000M | -3.40000M |
| Free cash flow | -151.60000M | 0.20M | -80.00000M | 75.10M | 75.10M |
Sector: Healthcare Industry: Diagnostics & Research
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| MYGN Myriad Genetics Inc |
0.31 6.44% | 5.12 | - | 2000.00 | 2.33 | 2.24 | 2.35 | -8.9577 |
| TMO Thermo Fisher Scientific Inc |
-9.89 1.94% | 500.08 | 34.71 | 23.87 | 4.62 | 4.43 | 5.29 | 20.89 |
| DHR Danaher Corporation |
-3.58 1.80% | 195.22 | 29.09 | 28.01 | 5.67 | 3.20 | 6.00 | 19.09 |
| A Agilent Technologies Inc |
-1.21 1.04% | 115.43 | 34.36 | 26.39 | 6.59 | 7.14 | 6.78 | 23.56 |
| IDXX IDEXX Laboratories Inc |
-11.6 1.90% | 598.85 | 49.99 | 45.66 | 11.29 | 27.85 | 11.46 | 34.46 |
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.
322 North 2200 West, Salt Lake City, UT, United States, 84116
| Name | Title | Year Born |
|---|---|---|
| Mr. Paul J. Diaz | CEO, Pres & Director | 1962 |
| Mr. R. Bryan Riggsbee | Exec. VP, CFO & Treasurer | 1971 |
| Ms. Nicole Lambert | Chief Operating Officer | 1974 |
| Mr. Mark S. Verratti | Chief Commercial Officer | 1968 |
| Ms. Natalie Munk | Principal Accounting Officer | 1981 |
| Dr. Kevin Richard Haas | Chief Technology Officer | 1986 |
| Dr. Dale Muzzey Ph.D. | Chief Scientific Officer | 1980 |
| Mr. Scott Gleason | Sr. VP of Investor Relations | 1979 |
| Dr. Clivetty Martinez | Chief Compliance Officer | NA |
| Ms. Pamela Wong | Chief Legal Officer | 1968 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...